Valneva SE
VLSNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for VLS. That does not mean none is planned.
Get an email about VLS's next catalysts
Track Valneva (VLS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Active
Chikungunya
Japanese Encephalitis purified inactivated vaccine (IC51)
Japanese Encephalitis
VLA1553
Chikungunya Virus Infection
Biological Vaccine VLA1553
Chikungunya Virus Infection
IC51
Japanese Encephalitis
AZD1222
SARS-CoV-2 Virus Infection
IXIARO
Japanese Encephalitis
VLA2001
SARS-CoV-2 Virus Infection
VLA15
Lyme Borreliosis
JE-VAX
Japanese Encephalitis
IC43
Pseudomonas Aeruginosa Infection
IC51 has given in the parent study IC51-322
Japanese Encephalitis
Japanese Encephalitis purified inactivated vaccine
Japanese Encephalitis
IC51 Japanese Encephalitis
Encephalitis
VLA1553 full dose
Chikungunya Virus Infection
IC41
Chronic Hepatitis C
VLA1701
Enterotoxigenic Escherichia Coli Infection
VLA84
Clostridium Difficile
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Active | Phase 3 | Chikungunya | - | - |
Japanese Encephalitis purified inactivated vaccine (IC51) | Phase 3 | Japanese Encephalitis | - | - |
VLA1553 | Phase 3 | Chikungunya Virus Infection | - | - |
Biological Vaccine VLA1553 | Phase 3 | Chikungunya Virus Infection | - | - |
IC51 | Phase 3 | Japanese Encephalitis | - | - |
AZD1222 | Phase 3 | SARS-CoV-2 Virus Infection | - | - |
IXIARO | Phase 3 | Japanese Encephalitis | - | - |
VLA2001 | Phase 3 | SARS-CoV-2 Virus Infection | - | - |
VLA15 | Phase 3 | Lyme Borreliosis | - | - |
JE-VAX | Phase 3 | Japanese Encephalitis | - | - |
IC43 | Phase 3 | Pseudomonas Aeruginosa Infection | - | - |
IC51 has given in the parent study IC51-322 | Phase 3 | Japanese Encephalitis | - | - |
Japanese Encephalitis purified inactivated vaccine | Phase 3 | Japanese Encephalitis | - | - |
IC51 Japanese Encephalitis | Phase 3 | Encephalitis | - | - |
VLA1553 full dose | Phase 2 | Chikungunya Virus Infection | - | - |
IC41 | Phase 2 | Chronic Hepatitis C | - | - |
VLA1701 | Phase 2 | Enterotoxigenic Escherichia Coli Infection | - | - |
VLA84 | Phase 2 | Clostridium Difficile | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Valneva SE's drug pipeline?→
CatalystAlert tracks 18 drug candidates in Valneva SE's (VLS) pipeline across Phase 3, Phase 2. Its lead program is Active (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Valneva SE's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Valneva SE (VLS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VLS biotech catalysts?→
Add VLS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Valneva SE's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.